Company Filing History:
Years Active: 2013
Title: Maigorzata Donata Gonciarz: Innovator in Pharmacological Advancements
Introduction
Maigorzata Donata Gonciarz is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of pharmacology, particularly in the development of variants of human fibroblast growth factor 21 (FGF21). Her work focuses on improving the pharmacological potency and stability of these variants, which are crucial for treating various metabolic disorders.
Latest Patents
Maigorzata holds a patent for "Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability." This invention relates to pharmacologically potent and/or stable variants of FGF21, pharmaceutical compositions comprising these variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants. She has 1 patent to her name.
Career Highlights
Maigorzata is currently employed at Eli Lilly and Company, where she continues to advance her research in pharmacology. Her work has the potential to significantly impact the treatment of metabolic diseases, making her a valuable asset to her organization and the scientific community.
Collaborations
Some of her notable coworkers include Craig Duane Dickinson and David A Driver, who contribute to her research efforts and collaborative projects.
Conclusion
Maigorzata Donata Gonciarz is a trailblazer in the field of pharmacology, with her innovative work on FGF21 variants paving the way for new treatments for metabolic disorders. Her contributions are essential in the ongoing fight against these prevalent health issues.